900909:SSEShanghai Huayi Group Corporation Ltd. Class B Analysis
Data as of 2026-05-31 - not real-time
$0.48
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Shanghai Huayi Group is trading at ¥0.478, well below its 20‑day (¥0.506), 50‑day (¥0.522) and 200‑day (¥0.534) simple moving averages, signaling a clear bearish technical backdrop. The RSI sits at 23, suggesting the stock is oversold, yet the MACD line remains under the signal line and the histogram is negative, reinforcing downward momentum. Volume has been shrinking, and the price hovers just above the computed support of ¥0.475, with the next resistance near ¥0.538. On the fundamentals side, the company posts a modest PE of 11.9, an ultra‑low price‑to‑book of 0.31 and a DCF‑derived fair value of about ¥11.44, indicating deep undervaluation. Despite thin margins (gross 7.5%, operating 2.5%) and sluggish revenue growth (1.6%), the balance sheet is strong: cash of ¥16.5 bn exceeds debt of ¥12.6 bn, leaving a net cash cushion. The dividend yield is an attractive 5.24% with a payout ratio around 66%, comfortably covered by free cash flow. Low beta (~0.19) points to limited market‑wide volatility, though 30‑day price swings are still around 19% and liquidity is waning. Overall, the stock sits at the intersection of technical weakness, substantial valuation upside, and solid cash‑generating capacity, making the outlook highly dependent on whether the market can price in its fundamentals.
Given the extreme‑greed market sentiment (Fear & Greed Index 94) and the current bearish technical signals, short‑term pressure may persist. However, the combination of a high dividend, net cash position, and a valuation gap suggests that patient investors could benefit from a potential mean‑reversion, especially if the chemical sector stabilises and regulatory pressures ease.
Given the extreme‑greed market sentiment (Fear & Greed Index 94) and the current bearish technical signals, short‑term pressure may persist. However, the combination of a high dividend, net cash position, and a valuation gap suggests that patient investors could benefit from a potential mean‑reversion, especially if the chemical sector stabilises and regulatory pressures ease.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below all major moving averages
- Decreasing trading volume
- Bearish MACD and negative histogram
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- High dividend yield with strong cash flow coverage
- Significant valuation upside (low P/B, DCF gap)
- Net cash position reduces financial risk
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Deep undervaluation relative to book and DCF
- Sustainable dividend and low payout ratio
- Low systematic risk (beta) and stable cash generation
Key Metrics & Analysis
Financial Health
Revenue Growth1.60%
Profit Margin1.22%
P/E Ratio11.9
ROE1.92%
ROA0.03%
Debt/Equity40.58
P/B Ratio0.3
Op. Cash Flow$6.5B
Free Cash Flow$1.4B
Technical Analysis
TrendBearish
RSI23.4
Support$0.47
Resistance$0.54
MA 20$0.51
MA 50$0.52
MA 200$0.53
MACDBearish
VolumeDecreasing
Fear & Greed Index94.07
Valuation
Fair Value$11.44
GradeUndervalued
TypeValue
Dividend Yield5.24%
Risk Assessment
Beta0.19
Volatility18.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.